Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients

Rheumatology

Volumn 39, Issue 10, 2000, Pages 1139-1146

  Choy, E H S ^a   Connolly, D J A ^a   Rapson, N ^b   Jeal, S ^b   Brown, J C C ^b   Kingsley, G H ^c   Panayi, G S ^a   Johnston, J M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

Author keywords

Anti CD4; Clinical response; Monoclonal antibodies; Pharmacodynamics; Pharmacokinetics; Rheumatoid arthritis

Indexed keywords

ACUTE PHASE PROTEIN; CD4 ANTIGEN; CHLORPHENIRAMINE; HYDROCORTISONE; IMMUNOGLOBULIN G1; IMMUNOMODULATING AGENT; INTERLEUKIN 6; MONOCLONAL ANTIBODY; OKT 4; RECOMBINANT HUMAN MONOCLONAL ANTIBODY 4162W94; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DYSPNEA; FEMALE; FEVER; HEADACHE; HUMAN; HYPOTENSION; IMMUNOTHERAPY; INFLAMMATION; LYMPHOCYTE COUNT; MALE; NAUSEA; PERIPHERAL CIRCULATION; PILOT STUDY; PRIORITY JOURNAL; RASH; RESPONSE TIME; RHEUMATOID ARTHRITIS; RIGOR; SYNOVIAL FLUID; T LYMPHOCYTE; TREATMENT OUTCOME; VOMITING;

EID: 0033787146     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/39.10.1139     Document Type: Article

References (31)

1. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis
2. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis
3. Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: A possible role of CD69
4. Interferon-gamma
5. Induction of tolerance in peripheral T cells with monoclonal antibodies
6. Mechanisms in CD4 antibody-mediated transplantation tolerance: Kinetics of induction, antigen dependence and role of regulatory T cells
7. Induction of tolerance by monoclonal antibody therapy
8. Treatment of rats with monoclonal anti-CD4 induces long-term resistance to streptococcal cell wall-induced arthritis
9. The development of insulin-dependent diabetes mellitus in non-obese diabetic mice: The role of CD4+ and CD8+ T cells
10. Treatment of a newly established transgenic model of chronic arthritis with nondepleting anti-CD4 monoclonal antibody
11. Anti-CD4 antibody treatment of patients with rheumatoid arthritis: I. Effect on clinical course and circulating T cells
12. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody
13. Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis
14. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody
15. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis
16. Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis
17. Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens
18. Role of cytokines in rheumatoid arthritis
19. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
20. Reshaping a therapeutic CD4 antibody
21. Comparison of expression of a humanized monoclonal antibody in mouse NSO myeloma cells and Chinese hamster ovary cells
22. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis
23. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis
24. A simple method for measuring patient anti- globulin responses against isotypic or idiotypic determinants
25. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis
26. Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome
27. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study
28. Treatment of refractory rheumatoid arthritis with chimaeric anti-CD4 antibody. Long-term follow up of CD4+ T cell counts
29. Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease
30. Differential functional effects of a humanized anti-CD4 antibody on resting and activated human T cells
31. Results of a placebo-controlled, multicenter trial using a primatized, non-depleting, anti-CD4 monoclonal antibody in the treatment of rheumatoid arthritis